GL1X · GenesisL1 explorer

Research workbench

SARS-cov-2 S ntd B.1.1.529 omicron variant + S309 local refinement

Analyse SARS-cov-2 S ntd B.1.1.529 omicron variant + S309 local refinement in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7TLZ
Type
protein
Length
475 residues
Chains
3
Method
electron microscopy
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
S2L20 Fab light chain; S2L20 Fab heavy chain; Spike glycoprotein
UniProt
P0DTC2
Ligands
NAG
Pockets
5 · best druggability 0.66

Structure

electron microscopy · 3 distinct chains · 3% helix, 50% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AS2L20 Fab light chainprotein1040% helix, 45% strand—
BS2L20 Fab heavy chainprotein1205% helix, 48% strand—
JSpike glycoproteinprotein2513% helix, 54% strandP0DTC2

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 6 copies · chains J, A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14990.660.7758empty
2600.630.9323empty
31050.510.8220empty
4860.450.8018empty
51010.370.7521empty

Interfaces

3 interfaces between chains.

  • A–B · 883 Ų buried · 8 hydrogen bonds · protein-protein
  • B–J · 730 Ų buried · 4 hydrogen bonds · protein-protein
  • A–J · 187 Ų buried · 0 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 6 glycan, 5 disulfide (N-glycosylation, disulfide).

Compared structures

  • 7TLZ · SARS-CoV-2 S NTD B.1.1.529 Omicron variant + S309 Local Refinement · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.